Effectiveness and safety of hydrogen inhalation therapy as an additional treatment for hypertension in real-world practice: a retrospective, observational study in China
Ji H, Sun H, Zhang Y, Zhao Z, Gao X, Wang C, Yang Y, Zhang X, Gao J, Man D, Yang Q, Yang Y, Yue C, Chen C, Ding X, Ni T. · Frontiers in cardiovascular medicine. 2024;11:1391282.
What kind of evidence is this?
Human
Prospective human study
Cardiovascular and circulatory health
Inhaled H₂
Not reported in this record.
Not reported in this record.
Methods at a glance
Human participants studied for cardiovascular and circulatory health. See eligibility criteria in the linked full text.
Human study; the full text reports 126 patients, with group/assay counts including n=1, n=305.
2.0 L/min
Full text reports inhaled H₂-containing gas. Detected intervention quantities or schedules: 2.0 L/min, 140 mm, 90 mm.
Inhaled molecular H₂; not classified as Brown’s gas without an H₂/O₂ composition.
H₂-related quantities reported in the intervention passages: 2.0 L/min, 140 mm, 90 mm. Values are not combined across different experimental arms.
Not reported in the full article — an absolute H₂ flow in mL/min could not be verified.
O₂ concentration and absolute O₂ flow were not both reported in the full article; no value is inferred.
Placebo or matched control reported in the full article.
Outcomes and reported result
clinical symptoms or functional scores, tumor growth or cancer markers, oxidative-stress and antioxidant markers, apoptosis or cell injury, histology or tissue damage, metabolic laboratory measures
Article-reported result excerpt (24 words maximum): “The SBP levels decreased in HI group (−5.93 mm Hg; 95% CI, −7.30 to −4.57) and control group (−1.31 mm Hg; 95% CI, −2.61…” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Human evidence; design, sample size and comparator limit interpretation. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies only to the population and protocol reported in this cardiovascular and circulatory health article.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 39600611 · DOI: 10.3389/fcvm.2024.1391282
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10